Clearside Biomedical, Inc. (CLSDQ) vs Oragenics, Inc. (OGEN)

Clearside Biomedical, Inc. and Oragenics, Inc. are both Biotechnology companies. Clearside Biomedical, Inc. and Oragenics, Inc. are of similar size ($2.2M and $2.0M). Clearside Biomedical, Inc. has negative trailing earnings, so its P/E is not meaningful; Oragenics, Inc. trades at 0.4×. Clearside Biomedical, Inc. grew revenue faster over the last twelve months: −56.8% against −75.1%. Oragenics, Inc. has the higher net margin (0.00% vs −780.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Clearside Biomedical, Inc. leads on 8 and Oragenics, Inc. on 7.

Valuation

Metric CLSDQ OGEN Biotechnology median
P/E n/m 0.38 8.50
P/S 0.39 15.40 9.71
P/B n/m 0.52 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.18 n/m 0.64
EV/Sales (1.24) 3.56 9.21
Earnings yield (2,075.24%) 259.93% (33.15%)
Free cash flow yield (1,661.90%) (534.75%) (25.50%)

Profitability

Metric CLSDQ OGEN Biotechnology median
Gross margin 92.55% 19.89% 65.16%
Operating margin (689.76%) 0.00% 0.00%
Net margin (780.93%) 0.00% 0.00%
Free cash flow margin (653.23%) 0.00% 0.00%
Return on equity 58.59% (1,307.07%) (56.36%)
Return on assets (127.43%) (264.23%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CLSDQ OGEN Biotechnology median
Revenue growth (TTM) (56.78%) (75.08%) 6.02%
EPS growth (last fiscal year) 11.32% 90.51% 30.26%
Revenue growth, 5-year CAGR (5.20%) (50.98%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLSDQ OGEN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.98 3.01 4.72
Net debt to EBITDA 0.69 0.98 0.96

Dividend

Metric CLSDQ OGEN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CLSDQ OGEN Biotechnology median
Market cap 2.15m 1.97m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack